Download presentation
Presentation is loading. Please wait.
Published byNelson Harrell Modified over 6 years ago
1
m-TOR inhibitors: What role in liver transplantation?
Toshiyasu Kawahara, Sonal Asthana, Norman M. Kneteman Journal of Hepatology Volume 55, Issue 6, Pages (December 2011) DOI: /j.jhep Copyright © 2011 European Association for the Study of the Liver Terms and Conditions
2
Fig. 1 Structures of sirolimus and everolimus.
Journal of Hepatology , DOI: ( /j.jhep ) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions
3
Fig. 2 An overview of the m-TOR signaling pathway and relative activities. Journal of Hepatology , DOI: ( /j.jhep ) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions
4
Fig. 3 Glomerular filtration rate (GFR) either with everolimus or cyclosporine A after liver transplantation. Significantly improved GFR was observed in the everolimus group from 1month after liver transplantation with early withdrawal of cyclosporine A. [28]. Journal of Hepatology , DOI: ( /j.jhep ) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions
5
Fig. 4 Creatinine clearance with everolimus or cyclosporine A after liver transplantation. Stable, but not improved renal function was observed after conversion from a calcineurin inhibitor to everolimus a relatively long mean time post-liver transplant (>3years) [29]. Journal of Hepatology , DOI: ( /j.jhep ) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.